Cases
Global Blood Therapeutics, Inc. (GBT)
Securities Class Action
Overview
Overview
- Date:
- 9/13/2018
- Company Name:
- Global Blood Therapeutics, Inc.
- Stock Symbol:
- GBT
- Status:
- Closed/Complete
NEW YORK, September 13, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against Global Blood Therapeutics, Inc. (GBT). Our investigation concerns whether Global Blood has violated the federal securities laws and/or engaged in other unlawful business practices.
On September 13, 2018, the website Stat published an article by Adam Feuerstein entitled “Global Blood’s FDA filing plan for a sickle cell drug is riskier than you think.” The article addressed Global Blood’s drug voxelotor, a potential sickle cell disease treatment, and described “important risks that investors might be glossing over” with respect to voxelotor’s FDA approval prospects. Citing the results of a recent Phase 3 clinical trial, the article asserted that “Global Blood lacks data demonstrating voxelotor reduces the frequency of crises,” traditionally a necessary criterion for FDA approval of a sickle cell disease treatment, and further stated that “[i]n the Phase 3 study, voxelotor did not improve the quality of life of sickle cell patients.” Accordingly, the article asserted that the Phase 3 results have “left Global Blood in a bind and searching for a new path to approval.”
On this news, Global Bloods’s share price fell over 7%, closing at $42.47 on September 13, 2018.
If you purchased or otherwise acquired Global Blood shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On September 13, 2018, the website Stat published an article by Adam Feuerstein entitled “Global Blood’s FDA filing plan for a sickle cell drug is riskier than you think.” The article addressed Global Blood’s drug voxelotor, a potential sickle cell disease treatment, and described “important risks that investors might be glossing over” with respect to voxelotor’s FDA approval prospects. Citing the results of a recent Phase 3 clinical trial, the article asserted that “Global Blood lacks data demonstrating voxelotor reduces the frequency of crises,” traditionally a necessary criterion for FDA approval of a sickle cell disease treatment, and further stated that “[i]n the Phase 3 study, voxelotor did not improve the quality of life of sickle cell patients.” Accordingly, the article asserted that the Phase 3 results have “left Global Blood in a bind and searching for a new path to approval.”
On this news, Global Bloods’s share price fell over 7%, closing at $42.47 on September 13, 2018.
If you purchased or otherwise acquired Global Blood shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.